BioBlog

Seven CEOs from the world’s largest pharmaceutical companies met with lawmakers on Capitol Hill for what some are calling a potential turning point in the public perception of the industry. The meetings focus on the continued outcry against the rising cost of drugs. For instance, insulin, which has

NCCN Academy for Excellence & Leadership in Oncology School of Pharmaceutical & Biotech Business3.20.19 Orlando, FLLearn about models for successful collaboration in practice management and Health Information Technology Payment, efficacy and outcomes are center stage in this week’s

This week’s Innovation Partners BioBlog explores the ideas, thinking, and policies that shape the debate around lowering the cost of healthcare and drugs. A new study finds that Medicare and Medicaid are better at keeping spending per beneficiary low. The Trump Administration may be putting more

This week’s Innovation Partners BioBlog reports on the accelerated timeline for Anthem’s new PBM as well as GlaxoSmithKline’s move to acquire Merck KGaA cancer immunotherapy. ASCO names treatments for rare cancer as the “Advance of the Year,” and the University of Pittsburgh School of Medicine’s

This week’s Innovation Partners BioBlog looks at changes to California’s Medicaid program that may shake up the current Medi-Cal system. Debate continues on step therapy in Medicare, Part B and Medicare unveiled a new app intended to help people determine what is covered. Oncologists and others

In this week’s Innovation Partners BioBlog, we look at a new payment model unveiled by CMS as well as new deals between Walmart and CVS. A doctor examines the pros and cons of dispensing oral oncolytics through clinics rather than specialty pharmacies. One hospital is waiving payments until the

This week’s Innovation Partners BioBlog provides a recap of key company news from the JPM Health Conference. GSK is changing direction and adding to its cancer drug pipeline, while Eli Lilly and Co has indicated it will not, for the time being, pursue CAR-T and gene therapy. Hospitals began

This week, the Innovation Partners BioBlog focuses on oncology research and drugs. Eli Lilly purchased Loxo Oncology this week while Sanofi and Regeneron extended and restructure their immune-oncology agreement. Takeda struck three new deals which will help their oncology R & D efforts, and Ribon